



21 August 2018

Creso Pharma strengthens its market presence in the UK through a commercial agreement with Pharmacare Europe to commercialize cannaQIX® and further products

Highlights:

- **Creso Pharma signs a commercial agreement with Pharmacare Europe for the marketing and distribution of its unique CBD hemp-based, human health nutraceutical product cannaQIX® and further products in the UK**
- **The products will be commercialized under the Pharmacare umbrella brand Naturopathica, laying the grounds for its presence in European markets**
- **Pharmacare is a key distributor to major UK and European retailers covering over 10,000 points of sales**
- **At the same time Creso Pharma is expanding its marketing and sales activities with Precision Health through its e-commerce platform from the UK with global reach**
- **Swiss regulatory authorities have issued a free sales certificate for the export of the products into the UK from Switzerland**

Creso Pharma Limited (ASX: CPH, the “Company” or “Creso”) is pleased to announce it has signed a commercial agreement with Pharmacare Europe, based in the UK, to market and distribute its CBD hemp-based human nutraceutical product cannaQIX® and further products in the UK and potentially in other European countries.

cannaQIX®, a unique standardised nutraceutical product in a proprietary delivery formulation, that contains organic full spectrum hemp extract with CBD, vitamins and zinc, has been developed to reduce stress and to support mental and nervous functions.

The launch will be implemented under the Pharmacare umbrella brand Naturopathica, one of many household brand names under Pharmacare, whose products can be found in tens of thousands of stores across Asia, America and Europe and who has over 10,000 points of sales in Europe alone.

Dr. Miri Halperin Wernli, Creso Pharma’s CEO and co-founder said: “We are really excited to commercialize cannaQIX® in the UK with Pharmacare Europe. I strongly believe that cannabis evolves to consumer branded products with varying delivery methods to suit everyone's different preferences and needs. With cannaQIX® we offer consumers a safe and effective certified Food Supplement with CBD which has broad market access without the need for medical prescription.

“Pharmacare’s success comes from its innovative nature, which fits well with our own passion for innovation. We see this partnership as a significant milestone in expanding our networks and positioning in the UK and in Europe more broadly.”



Trishina Singh of PharmaCare Europe stated: “We are looking forward to partnering with Creso Pharma and working on their exciting, innovative and diverse product portfolio. With our established networks across Europe and increasing demand for products of this type, we believe it will be a really successful collaboration.”

The launch is planned for October 2018.

At the same time as signing this agreement, Creso Pharma is expanding its marketing and sales activities with Precision Health through its e-commerce platform from the UK with global reach. This marketing and commercial effort will allow Creso to reach new markets in which it has not yet established a presence.

About cannaQIX®



The cannaQIX® range of products are CBD hemp-based nutraceuticals using Creso’s proprietary innovative delivery technology. They contain full spectrum organic hemp extract with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions.

The proprietary QIX-technology based delivery system contains capsiicum, which accelerates the blood circulation in the mouth enhancing the buccal sublingual delivery of the CBD, vitamins and zinc into the bloodstream. The product is safe, well tolerated, non-euphoric, non-addictive and sugar free.

The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect over several days.

The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a “Swiss Made” label.

-ENDS-



Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW 2000
E: info@everblucapital.com
P: +61 2 8249 0000

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About Pharmacare Europe

pharmacareeurope.com

Pharmacare Europe operates in Europe and the Middle East, across pharmacy, retail and online channels. PharmaCare launched into the European market in 2007 with Skin Doctors™, a leading cosmeceutical brand that transformed skincare marketing from product-led, to concern-led. This success was followed by the launch of Sambucol, black elderberry supplement. Sambucol is now a household brand in a number of EMEA countries and is fast becoming a favourite natural product for immunity support.

2010 saw the launch of Bioglan, Pharmacare's fastest-growing brand operating within fish oils, joint health, heart health, multivitamins and probiotics, gradually expanding into other categories.

In 2011 Pharmacare acquired Promensil and Menoflavon, household brand names within the natural menopause support category.

PharmaCare Europe brands are largely distributed in many markets across Europe and beyond.

About Domaco, Dr. med Aufdermaur AG

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.



Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.